Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...

Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

Novo Nordisk, a leading Danish pharmaceutical company ... prices dipped nearly 5% following disappointing Phase 2a trial results of another obesity drug, monlunabant. While the drug, acquired through ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

Capital Expenditure: DKK31.1 billion, compared to DKK16.4 billion in 2023. Novo Nordisk AS (NYSE:NVO) reported a 24% sales growth and 22% operating profit growth for the first nine months of 2024 ...

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...

Novo Nordisk ( (NVO)) has released its Q3 earnings. Here is a breakdown of the information Novo Nordisk presented to its investors. Novo Nordisk is a global healthcare company specializing in ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...